TTG Tutogen Medical,

ALACHUA, Fla., May 9 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc. (AMEX:TTG), announced today that it has entered into a new international distribution agreement for its allograft and Tutoplast Bovine Pericardium tissues for urological procedures with Coloplast Corporation. The agreement replaces the current distribution agreement where Coloplast has been the exclusive distributor of Tutogen allograft products for urological procedures in the United States since acquiring the Mentor Urology business in June 2006. Guy Mayer, President and Chief Executive Officer of Tutogen Medical, commented, "We are very pleased to expand our distribution relationship with Coloplast. They are a highly regarded market leader both in the U.S. and internationally. We firmly believe that the international urology market offers significant opportunities for our leading-edge sterile grafts and we could not have a better distribution partner than Coloplast. We look forward to developing these new opportunities together." Mr. Mayer continued, "In a related matter, we expect that our Tutoplast Bovine Pericardium will soon be available in the U.S. The tissues have been very well received in Europe over the past few years and we expect that to be the case in the U.S. as well. Our tissues will be the only new xenograft product to be backed by several years of clinical experience and we believe that this provides us an important competitive advantage." About Tutogen Medical, Inc. Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its proprietary Tutoplast Process(R) of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, and general surgery procedures. The Company's Tutoplast(R) products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of C.R. Bard Inc., the Mentor Corporation (Mentor), Coloplast Corp., IOP, Inc. and through independent distributors internationally. For more information, visit the Company's Web site at http://www.tutogen.com/. Forward-Looking Statement Disclaimer: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. Forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These and other risks are identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2006. All information in this press release is as of the date hereof, and the Company undertakes no duty to update this information unless required by law. Contacts: L. Robert Johnston, Jr. Lytham Partners, LLC Chief Financial Officer Joe Diaz Tutogen Medical, Inc. Joe Dorame 386-462-0402 Robert Blum 602-889-9700 DATASOURCE: Tutogen Medical, Inc. CONTACT: L. Robert Johnston, Jr., Chief Financial Officer of Tutogen Medical, Inc., +1-386-462-0402, ; or Joe Diaz, or Joe Dorame, or Robert Blum, all of Lytham Partners, LLC, +1-602-889-9700, for Tutogen Medical, Inc. Web site: http://www.tutogen.com/

Copyright